132 related articles for article (PubMed ID: 8781777)
1. Distribution of tacrine and metabolites in rat brain and plasma after single- and multiple-dose regimens. Evidence for accumulation of tacrine in brain tissue.
McNally WP; Pool WF; Sinz MW; Dehart P; Ortwine DF; Huang CC; Chang T; Woolf TF
Drug Metab Dispos; 1996 Jun; 24(6):628-33. PubMed ID: 8781777
[TBL] [Abstract][Full Text] [Related]
2. Metabolic disposition of the cognition activator tacrine in rats, dogs, and humans. Species comparisons.
Pool WF; Reily MD; Bjorge SM; Woolf TF
Drug Metab Dispos; 1997 May; 25(5):590-7. PubMed ID: 9152598
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective hydroxylation of tacrine in rats and humans.
Hooper WD; Pool WF; Woolf TF; Gal J
Drug Metab Dispos; 1994; 22(5):719-24. PubMed ID: 7835223
[TBL] [Abstract][Full Text] [Related]
4. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy.
Laine K; Palovaara S; Tapanainen P; Manninen P
Clin Pharmacol Ther; 1999 Dec; 66(6):602-8. PubMed ID: 10613616
[TBL] [Abstract][Full Text] [Related]
5. [Synthesis of prodrugs of tacrine hydrochloride and evaluation of the stability and biodistribution in mice].
Jiang Y; Zhang Y; Zhang ZR
Yao Xue Xue Bao; 2003 Dec; 38(12):962-5. PubMed ID: 15040096
[TBL] [Abstract][Full Text] [Related]
6. Identification of the urinary metabolites of tacrine in the rat.
Hsu RS; Shutske GM; Dileo EM; Chesson SM; Linville AR; Allen RC
Drug Metab Dispos; 1990; 18(5):779-83. PubMed ID: 1981736
[TBL] [Abstract][Full Text] [Related]
7. Metabolic disposition of tacrine in primary suspensions of rat hepatocyte and in single-pass perfused liver: in vitro/in vivo comparisons.
Kukan M; Bezek S; Pool WF; Woolf TF
Xenobiotica; 1994 Nov; 24(11):1107-17. PubMed ID: 7701852
[TBL] [Abstract][Full Text] [Related]
8. The effect of cytochromes P4501A induction and inhibition on the disposition of the cognition activator tacrine in rat hepatic preparations.
Bezek S; Kukan M; Pool WF; Woolf TF
Xenobiotica; 1996 Sep; 26(9):935-46. PubMed ID: 8893040
[TBL] [Abstract][Full Text] [Related]
9. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference.
Woolf TF; Pool WF; Bjorge SM; Chang T; Goel OP; Purchase CF; Schroeder MC; Kunze KL; Trager WF
Drug Metab Dispos; 1993; 21(5):874-82. PubMed ID: 7902251
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tacrine oral clearance by cimetidine.
Forgue ST; Reece PA; Sedman AJ; deVries TM
Clin Pharmacol Ther; 1996 Apr; 59(4):444-9. PubMed ID: 8612390
[TBL] [Abstract][Full Text] [Related]
11. Cholinesterase inhibitor therapy for Alzheimer dementia: what do animal models tell us?
Sherman KA; Messamore E
Prog Clin Biol Res; 1989; 317():1209-22. PubMed ID: 2602408
[TBL] [Abstract][Full Text] [Related]
12. Metabolic response to tacrine (THA) and physostigmine in the aged rat brain.
Bassant MH; Jazat-Poindessous F; Lamour Y
J Cereb Blood Flow Metab; 1995 Nov; 15(6):1093-102. PubMed ID: 7593342
[TBL] [Abstract][Full Text] [Related]
13. Nose-to-brain delivery of tacrine.
Jogani VV; Shah PJ; Mishra P; Mishra AK; Misra AR
J Pharm Pharmacol; 2007 Sep; 59(9):1199-205. PubMed ID: 17883890
[TBL] [Abstract][Full Text] [Related]
14. Saturable distribution of tacrine into the striatal extracellular fluid of the rat: evidence of involvement of multiple organic cation transporters in the transport.
Sung JH; Yu KH; Park JS; Tsuruo T; Kim DD; Shim CK; Chung SJ
Drug Metab Dispos; 2005 Mar; 33(3):440-8. PubMed ID: 15547049
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.
Camps P; El Achab R; Görbig DM; Morral J; Muñoz-Torrero D; Badia A; Eladi Baños J; Vivas NM; Barril X; Orozco M; Luque FJ
J Med Chem; 1999 Aug; 42(17):3227-42. PubMed ID: 10464010
[TBL] [Abstract][Full Text] [Related]
16. Effect of tetrahydroaminoacridine on sleep in healthy subjects.
Riemann D; Lis S; Fritsch-Montero R; Meier T; Krieger S; Hohagen F; Berger M
Biol Psychiatry; 1996 May; 39(9):796-802. PubMed ID: 8731520
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 2nd communication: distribution to organs and tissues in male, female and pregnant rats, and characteristics of protein binding in plasma.
Steinke W; Ahr HJ; Hirayama M
Arzneimittelforschung; 1997 Aug; 47(8):939-48. PubMed ID: 9296280
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease.
Smith CP; Bores GM; Petko W; Li M; Selk DE; Rush DK; Camacho F; Winslow JT; Fishkin R; Cunningham DM; Brooks KM; Roehr J; Hartman HB; Davis L; Vargas HM
J Pharmacol Exp Ther; 1997 Feb; 280(2):710-20. PubMed ID: 9023283
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
20. Mechanism for increased bioavailability of tacrine in fasted rats.
Sung JH; Hong SS; Ahn SH; Li H; Seo SY; Park CH; Park BS; Chung SJ
J Pharm Pharmacol; 2006 May; 58(5):643-9. PubMed ID: 16640833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
